What is the effect of obesity on piperacillin and meropenem trough concentrations in critically ill patients?

Alobaid, Abdulaziz S., Brinkmann, Alexander, Frey, Otto R., Roehr, Anka C., Luque, Sonia, Grau, Santiago, Wong, Gloria, Abdul-Aziz, Mohd-Hafiz, Roberts, Michael S., Lipman, Jeffrey and Roberts, Jason A. (2016) What is the effect of obesity on piperacillin and meropenem trough concentrations in critically ill patients?. Journal of Antimicrobial Chemotherapy, 71 3: 696-702. doi:10.1093/jac/dkv412


Author Alobaid, Abdulaziz S.
Brinkmann, Alexander
Frey, Otto R.
Roehr, Anka C.
Luque, Sonia
Grau, Santiago
Wong, Gloria
Abdul-Aziz, Mohd-Hafiz
Roberts, Michael S.
Lipman, Jeffrey
Roberts, Jason A.
Title What is the effect of obesity on piperacillin and meropenem trough concentrations in critically ill patients?
Journal name Journal of Antimicrobial Chemotherapy   Check publisher's open access policy
ISSN 1460-2091
0305-7453
Publication date 2016-03-01
Year available 2016
Sub-type Article (original research)
DOI 10.1093/jac/dkv412
Open Access Status Not Open Access
Volume 71
Issue 3
Start page 696
End page 702
Total pages 7
Place of publication Oxford, United Kingdom
Publisher Oxford University Press
Collection year 2017
Language eng
Formatted abstract
Objectives The objectives of this study were to determine the effects of obesity on unbound trough concentrations and on the achievement of pharmacokinetic (PK)/pharmacodynamic (PD) targets of piperacillin and meropenem in critically ill patients.

Methods This study retrospectively analysed therapeutic-drug-monitoring data from ICU databases in Australia, Germany and Spain, as well as from a large PK study. The presence of obesity was defined as a BMI ≥30 kg/m2, and patients were also categorized based on level of renal function. The presence of obesity was compared with unbound piperacillin and meropenem trough concentrations. We also used logistic regression to describe factors associated with the achievement of the PK/PD targets, an unbound concentration maintained above the MIC breakpoint (100% fT>MIC and 100% fT>4×MIC) of Pseudomonas aeruginosa.

Results In all, 1400 patients were eligible for inclusion in the study. The median age and weight were 67 years (IQR 52–76 years) and 79 kg (69–90 kg), respectively, and 65% of participants were male. Significantly lower median piperacillin trough concentrations [29.4 mg/L (IQR 17.0–58.0 mg/L)] were found in obese patients compared with non-obese patients [42.0 mg/L (21.5–73.5 mg/L)] (P = 0.001). There was no difference for meropenem trough concentrations [obese 10.3 mg/L (IQR 4.8–16.0 mg/L) versus non-obese 11.0 mg/L (4.3–18.5 mg/L); P = 0.296]. Using logistic regression, we found that the presence of obesity was not associated with achievement of 100% fT>MIC, but the use of prolonged infusion, a creatinine clearance ≤100 mL/min, increasing age and female gender were for various PK/PD targets for both piperacillin and meropenem (P < 0.05).

Conclusions This large dataset has shown that the presence of obesity in critically ill patients may affect piperacillin, but not meropenem, unbound trough concentrations.
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: HERDC Pre-Audit
Admin Only - School of Medicine
School of Medicine Publications
School of Pharmacy Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 2 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 2 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 29 Mar 2016, 00:48:43 EST by System User on behalf of School of Medicine